Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
15 avr. 2020 08h30 HE
|
Celsion CORP
Independent Data Monitoring Committee is Expected to Meet in July 2020 to Evaluate Overall Survival Data LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
Celsion Corporation to Participate in Two Investor Conferences in May 2019
12 avr. 2019 08h30 HE
|
Celsion CORP
Company to Discuss its Ongoing Pivotal Phase III Study in Primary Liver Cancer and its Phase I/II Clinical Study in Ovarian Cancer LAWRENCEVILLE, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Celsion...